Leerink Partnrs Issues Optimistic Estimate for NBIX Earnings

Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) - Stock analysts at Leerink Partnrs boosted their Q3 2025 earnings estimates for Neurocrine Biosciences in a research note issued on Thursday, July 10th. Leerink Partnrs analyst M. Goodman now expects that the company will post earnings per share of $1.58 for the quarter, up from their previous estimate of $1.52. The consensus estimate for Neurocrine Biosciences' current full-year earnings is $4.28 per share. Leerink Partnrs also issued estimates for Neurocrine Biosciences' FY2026 earnings at $6.30 EPS and FY2027 earnings at $8.40 EPS.

Neurocrine Biosciences (NASDAQ:NBIX - Get Free Report) last issued its earnings results on Monday, May 5th. The company reported $0.08 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.70 by ($0.62). Neurocrine Biosciences had a return on equity of 11.81% and a net margin of 12.68%. The firm had revenue of $572.60 million during the quarter, compared to the consensus estimate of $587.06 million. During the same quarter in the prior year, the business posted $1.20 EPS. The firm's revenue for the quarter was up 11.1% on a year-over-year basis.

A number of other brokerages have also commented on NBIX. The Goldman Sachs Group initiated coverage on Neurocrine Biosciences in a research note on Thursday. They issued a "buy" rating and a $182.00 price target for the company. Wedbush reissued an "outperform" rating on shares of Neurocrine Biosciences in a research report on Tuesday, May 6th. BMO Capital Markets raised their price objective on Neurocrine Biosciences from $96.00 to $115.00 and gave the company a "market perform" rating in a research report on Tuesday, May 6th. Evercore ISI lowered their price objective on Neurocrine Biosciences from $190.00 to $185.00 and set an "outperform" rating for the company in a research report on Thursday, April 24th. Finally, Wall Street Zen lowered Neurocrine Biosciences from a "strong-buy" rating to a "buy" rating in a research report on Thursday, March 20th. Three research analysts have rated the stock with a hold rating and twenty-one have assigned a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $163.91.

Neurocrine Biosciences Stock Performance

NBIX stock traded up $1.67 on Monday, reaching $135.13. The company's stock had a trading volume of 613,126 shares, compared to its average volume of 1,326,868. The business has a fifty day simple moving average of $124.19 and a two-hundred day simple moving average of $121.53. Neurocrine Biosciences has a 12-month low of $84.23 and a 12-month high of $157.98. The firm has a market cap of $13.37 billion, a PE ratio of 45.81, a PEG ratio of 1.37 and a beta of 0.24.

Insider Transactions at Neurocrine Biosciences

In related news, Director Kevin Charles Gorman sold 9,613 shares of the business's stock in a transaction that occurred on Tuesday, May 27th. The stock was sold at an average price of $120.38, for a total transaction of $1,157,212.94. Following the completion of the transaction, the director directly owned 514,596 shares in the company, valued at approximately $61,947,066.48. The trade was a 1.83% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Ingrid Delaet sold 457 shares of the business's stock in a transaction that occurred on Thursday, July 10th. The shares were sold at an average price of $135.00, for a total value of $61,695.00. Following the transaction, the insider owned 4,730 shares of the company's stock, valued at approximately $638,550. This trade represents a 8.81% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 120,251 shares of company stock valued at $14,978,602. 4.80% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in NBIX. Avantax Advisory Services Inc. lifted its holdings in Neurocrine Biosciences by 11.4% in the 4th quarter. Avantax Advisory Services Inc. now owns 2,895 shares of the company's stock worth $395,000 after purchasing an additional 297 shares in the last quarter. Corient Private Wealth LLC raised its holdings in shares of Neurocrine Biosciences by 64.0% during the 4th quarter. Corient Private Wealth LLC now owns 7,927 shares of the company's stock worth $1,082,000 after acquiring an additional 3,094 shares in the last quarter. B. Metzler seel. Sohn & Co. AG raised its holdings in shares of Neurocrine Biosciences by 5.1% during the 4th quarter. B. Metzler seel. Sohn & Co. AG now owns 5,044 shares of the company's stock worth $689,000 after acquiring an additional 245 shares in the last quarter. Golden State Wealth Management LLC raised its holdings in shares of Neurocrine Biosciences by 116.9% during the 1st quarter. Golden State Wealth Management LLC now owns 397 shares of the company's stock worth $44,000 after acquiring an additional 214 shares in the last quarter. Finally, Fifth Third Bancorp raised its holdings in shares of Neurocrine Biosciences by 31.7% during the 1st quarter. Fifth Third Bancorp now owns 1,056 shares of the company's stock worth $117,000 after acquiring an additional 254 shares in the last quarter. 92.59% of the stock is currently owned by institutional investors.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.